Aim: To evaluate the levels of soluble CTLA-4 (s CTLA-4) in sera of celiac disease (CD) patients with overlapping autoimmune diseases (OAD; diabetes mellitus, autoimmune thyroid diseases, inflammatory bowel diseases, and autoimmune polyendocrine syndromes). Methods: Sera from Italian patients with CD were obtained and enzyme-linked immunosorbent assay (ELISA) was used to measure sCTLA-4. Results: Consistently high serum sCTLA-4 levels were observed in CD (13.20 ng/ml, p < 0.0001), and OAD (19.48 ng/ml, p < 0.0001) compared to normal controls. A significant increase in the level of serum sCTLA-4 was observed in OAD (p = 0.0273) compared to CD alone. At variance, no significant difference in the sCTLA-4 levels was observed when single overlapping autoimmune diseases were compared. Conclusion: The present study shows for the first time a statistically significant increase of serum sCTLA-4 levels in CD patients with associated autoimmune disease (namely, CD and OAD) vs. patients with CD alone. Previously, the potential genetic associations of several CTLA-4 polymorphisms to susceptibility to autoimmune diseases have been described, although the relationship between CTLA-4 polymorphisms and the ability to produce the soluble form is not fully clarified. CTLA-4 is a strong actor in the adaptive response: our data give supportive evidence of the common background of autoimmune diseases.

Oversecretion of soluble CTLA-4 in various autoimmune diseases overlapping celiac disease.

PESCE, GIAMPAOLA;BAGNASCO, MARCELLO;SAVERINO, DANIELE
2014

Abstract

Aim: To evaluate the levels of soluble CTLA-4 (s CTLA-4) in sera of celiac disease (CD) patients with overlapping autoimmune diseases (OAD; diabetes mellitus, autoimmune thyroid diseases, inflammatory bowel diseases, and autoimmune polyendocrine syndromes). Methods: Sera from Italian patients with CD were obtained and enzyme-linked immunosorbent assay (ELISA) was used to measure sCTLA-4. Results: Consistently high serum sCTLA-4 levels were observed in CD (13.20 ng/ml, p < 0.0001), and OAD (19.48 ng/ml, p < 0.0001) compared to normal controls. A significant increase in the level of serum sCTLA-4 was observed in OAD (p = 0.0273) compared to CD alone. At variance, no significant difference in the sCTLA-4 levels was observed when single overlapping autoimmune diseases were compared. Conclusion: The present study shows for the first time a statistically significant increase of serum sCTLA-4 levels in CD patients with associated autoimmune disease (namely, CD and OAD) vs. patients with CD alone. Previously, the potential genetic associations of several CTLA-4 polymorphisms to susceptibility to autoimmune diseases have been described, although the relationship between CTLA-4 polymorphisms and the ability to produce the soluble form is not fully clarified. CTLA-4 is a strong actor in the adaptive response: our data give supportive evidence of the common background of autoimmune diseases.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11567/611141
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact